ReviewNanotheranostics2017
Prediction of Anti-cancer Nanotherapy Efficacy by Imaging.
Review in Nanotheranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Comparison of methods for in vivo and ex vivo quantification of iron in murine brain tumors.PloS one · 2026Article
- Evaluation of CoFeInternational journal of molecular sciences · 2025Article
- Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025Review
- Development of Resorbable Phosphate-Based Glass Microspheres as MRI Contrast Media Agents.Molecules (Basel, Switzerland) · 2024Article
- Challenges and advances for glioma therapy based on inorganic nanoparticles.Materials today. Bio · 2023Review
- IONPs-Based Medical Imaging in Cancer Care: Moving Beyond Traditional Diagnosis and Therapeutic Assessment.International journal of nanomedicine · 2023Review
- Supermagnetic Human Serum Albumin (HSA) Nanoparticles and PLGA-Based Doxorubicin Nanoformulation: A Duet for Selective Nanotherapy.International journal of molecular sciences · 2022Article
- Deciphering albumin-directed drug delivery by imaging.Advanced drug delivery reviews · 2022Review
- Multiplexed imaging in oncology.Nature biomedical engineering · 2022Review
- Research on DCE-MRI Images Based on Deep Transfer Learning in Breast Cancer Adjuvant Curative Effect Prediction.Journal of healthcare engineering · 2022Article
- Current Status of Brain Tumor in the Kingdom of Saudi Arabia and Application of Nanobiotechnology for Its Treatment: A Comprehensive Review.Life (Basel, Switzerland) · 2021Review
- Stimuli-Responsive Iron Oxide Nanotheranostics: A Versatile and Powerful Approach for Cancer Therapy.Advanced healthcare materials · 2021Review
- The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.Chemical reviews · 2021Review
- Macrophage imaging and subset analysis using single-cell RNA sequencing.Nanotheranostics · 2021Article
- Aptamer-Targeted Calcium Phosphosilicate Nanoparticles for Effective Imaging of Pancreatic and Prostate Cancer.International journal of nanomedicine · 2021Article
- Intraoperative assessment and postsurgical treatment of prostate cancer tumors using tumor-targeted nanoprobes.Nanotheranostics · 2021Article
- Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.Radiology · 2021Article
- Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy.Science advances · 2020Article
- Photodynamic Therapy and the Biophysics of the Tumor Microenvironment.Photochemistry and photobiology · 2020Review
- The Therapeutic Potential of Nanobodies.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Anticancer nanotherapeutics have shown mixed results in clinical trials, raising the questions of whether imaging should be used to i) identify patients with a higher likelihood of nanoparticle accumulation, ii) assess nanotherapeutic efficacy before traditional measures show response, and iii) guide adjuvant treatments to enhance therapeutic nanoparticle (TNP) delivery. Here we review the use of a clinically approved MRI nanoparticle (ferumoxytol, FMX) to predict TNP delivery and efficacy. It is becoming increasingly apparent that nanoparticles used for imaging, despite clearly distinct physicochemical properties, often co-localize with TNP in tumors. This evidence offers the possibility of using FMX as a generic "companion diagnostic" nanoparticle for multiple TNP formulations, thus potentially allowing many of the complex regulatory and cost challenges of other approaches to be avoided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.